Factors to watch on Dec 7

December 7, 2015 5:35 AM

33 0

* Novartis said phase III studies of Jakavi showed disease improvement in patients with myelofibrosis and polycythemia vera. New CTL019 study data demonstrated overall response in adult patients with certain types of lymphoma, Novartis said.

* Roche said new results from a CLL11 study showed Gazyva/Gazyvaro provided people with previously untreated chronic lymphocytic leukaemia a treatment-free period of nearly four years.

Also read: New Drug Combinations Improve Survival in Lung Cancer

Read more

To category page